BioMerica Inc. (BMRA)

[badman]

Hmmm...ConnectTheDots...oldmanbadman rdncoic

Biomerica (NASDAQ: BMRA) had its outperform rating reissued by analysts at Zacks. The firm currently has a $2.70 target price on the stock. Zacks’ analyst wrote, “Biomerica has been profitable over nine of the last ten quarters, has regularly generated positive cash flow, and maintains a stellar balance sheet. We think it is clear that management and the board lead the company in a way with an eye on increasing shareholder value. We have come across few companies that have been in existence over 40 years, possess all of the positive characteristics of BMRA and yet trade at what we would characterize as an incredibly cheap valuation. We see very little to no downside risk in the share price at this level. We think the cheap valuation may have more to do with BMRA being a nano-cap and suffering from a lack of exposure rather than having anything to do with fundamentals. “

Informed investors can connect the dots before the un-informed strap hangers even can start to onderstand what is going on. Do your due diligence and be prepared...........oldmanbadman rdncoic

Why else would an investor jump in now with a 5% buy at a premium, $1.25 a share, if the big boys didn't know what was going on? :):) :)